List view / Grid view
14 March 2019 | By Nikki Withers (European Pharmaceutical Review)
The FDA has prioritised the review of this drug application after multiple recalls of generic valsartan products from several manufacturers...
7 March 2019 | By European Pharmaceutical Review
Colour-coded generics might help consumers differentiate between generics and branded medicines...
21 February 2019 | By European Pharmaceutical Review
The EU is adopting new rules which should boost the competitiveness of EU producers of generic medicines and biosimilar products...
21 January 2019 | By Nikki Withers (European Pharmaceutical Review)
Of the 21 drugs designed for delivery directly to the female genital tract, only four have a cost-effective, generic equivalent...
8 January 2019 | By Nikki Withers (European Pharmaceutical Review)
The rising costs of brand-name drugs is largely driven by inflation in the prices of widely used existing drugs, according to a study published in the January issue of Health Affairs...
5 October 2018 | By Mike Stones
North America dominates the global market for pharmaceutical glass packaging, due to the region’s technical innovation and strong demand for pharmaceutical products...
19 June 2018 | By European Pharmaceutical Review
The FDA has approved the first generic versions of Suboxone sublingual film for the treatment of opioid dependence...
14 March 2018 | By European Pharmaceutical Review
A study in Canada has demonstrated that generic antiplatelet drugs appear to be as equally effective as a brand name drug for heart patients.
14 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
10 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A report released has identified a two-tier manufacturing market and forecast increased acquisitions by Indian companies...
21 July 2015 | By Victoria White
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.
Follow: